Puncture site bleeding complications in patients with Clopidogrel hyper-response: Three case reports by Žarko, Nedeljković et al.
Romanian Neurosurgery (2020) XXXIV (1): pp. 52-59 
DOI: 10.33962/roneuro-2020-008 
www.journals.lapub.co.uk/index.php/roneurosurgery 
 
 
 
Puncture site bleeding complications in 
patients with Clopidogrel hyper-response. 
Three case reports  
 
 
Nedeljković Žarko1, Vukasinović Ivan2, Majstorović 
Branisalva3, Milosević Medenica Svetlana2, 
Milićević Mihailo1, Ilić Rosanda1, Aleksić Vuk1, 
Paunović Aleksandra1, Stanimirovic Aleksandar1, 
Scepanović Vuk1, Milić Marina1, Todorović Marko1, 
Milisavljević Filip1, Grujičić Danica1 
 
1 Clinic for Neurosurgery, Clinical Center of SERBIA 
2 Center for Radiology and Magnetic Resonance, Clinical Center of 
SERBIA 
3 Center for Anesthesiology, Clinical Center of SERBIA 
 
 
 
 
ABSTRACT 
Dual antiplatelet therapy (clopidogrel and acetylsalicylic acid) is a standard for the 
embolization of planned intracranial aneurysms with CNS stent due to the possibility 
of stent thrombus formation. All anti-aggregation drugs, including those listed, have 
bleeding as a side effect. Three patients with aneurysm had an elevated response to 
antiplatelet therapy with clopidogrel, which was confirmed by a multiplate test on the 
"VerifyNow" system. After reducing the dose of clopidogrel or after interrupting it, 
with the introduction of low molecular weight heparin for the duration of five days, 
aneurysms were successfully resolved by intracranial implantation of the stent. 
Perioperative angiograms and postoperative CT angiograms have verified 
hematomas at the place of punction of the femoral artery. Bleeding was resolved by 
the femoral artery suture by a vascular surgeon. All patients were discharged home 
without further complications and with dual antiplatelet therapy. By measuring the 
platelet function in vitro, the degree of inhibition of platelet activity achieved by the 
action of the drug can be assessed. A specific test can identify those patients who are 
highly responsive to the drug with increased platelet reactivity and the possibility of 
increased risk of bleeding. Our suggestion is to reduce the dosage of clopidogrel or 
to leave it out for 24 hours with preventive doses of low molecular weight heparin or 
to change the strategy of treatment of intracranial aneurysm, i.e. avoiding 
implantation of CNS stent. 
 
 
INTRODUCTION 
According to statistics, about 5% of the population has intracranial 
aneurysm, out of which 1 to 2% suffer from aneurysm rupture with a 
dramatic clinical manifestations and consequences [1,2,3].Today, it is  
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believed that endovascular treatment is a better, 
more modern and less aggressive treatment 
associated with less complications and lower 
mortality, shorter length of hospital stay and lower 
costs of treatment compared to conventional 
neurosurgical treatment, i.e. microsurgical clipping 
of aneurysms [4,5,6,7,8]. The current standard of 
preoperative preparation for stent placement in 
aneurysms involves dual antiplatelet therapy with 
acetylsalicylic acid and clopidogrel.Antiplatelet drugs 
inhibit platelet aggregation and thus stop the 
formation of thrombus. Thrombus formation is a 
complex mechanism of responses to vascular 
changes, injuries, atherosclerosis and other 
diseases.The data indicate that in addition to the 
effect of these drugs, other local and systemic factors 
(diabetes mellitus, left ventricular hypertrophy, atrial 
fibrillation) may be the cause of unwanted ischemic 
events [9,10]. Other antiplatelet drugs: prasugrel, 
dipyridamole, cilostazol, cangrelor and ticagrelor 
have not been analyzed so far, andtherefore are the 
subject of recent researches that are yet to define the 
benefits of their application in therapy. 
 
CASE 1 
Pre-procedural angiograms showed the condition of 
59-year-old patient, after the coiling of ACI 
aneurysms on both sides. From the medical 
documentation, it is learned that the patient's 
embolization of aneurysms was done on both 
internal carotid arteries in 2016. Hematological 
parameters on admision: RBC 4,75x10 12 /L, Hgb 138 
g/L, Hct 0,45 L/L. Due to the impaction of the coilling 
to the right internal carotid artery, placement of the 
stent was planned, therefore, three days before the 
intervention, the patient was administered 
clopidogrel75 mg twice daily and acetylsalicylic acid 
100 mg once a day. Drug-resistence testing on the 
„VerifyNow” device showed an increased sensitivity 
of platelet activity to the action of clopidogrel. 
Clopidogrel was discontinued for fivedays and 
acetylsalicylic acid was continued. During this period, 
a low molecular weight heparin is administered at a 
dose of 0,3 ml twice a day, and then it was proceeded 
to the procedure. By accessing the left femoral 
artery, the Flow diverting Silc 3x20mm stent is placed 
over the aneurysm`s neck on the right internal 
carotid artery, which causes the pathway obstruction 
of the contrast agent in aneurysm. During puncture 
there was perforation of the left femoral artery and 
extravasation of the contrast medium with the 
expansion pathway caudally. The intervention was 
interrupted, the puncture site waspressed with long-
term compression in groin. The patient complained 
of pain in the left side of abdomen. Physical 
examination found palpatory pain sensation of the 
abdomen and drop in blood pressure.CT 
angiography of the leg and abdomen showed the 
extravasation of the contrast agent at the level of the 
left femoral artery with expansion towards the 
retroperitoneum.[Figure 1, Figure 2]. 
 
 
 
Figure 1. Angiographic presentation of aneurysms and CT 
angiographic exploration of bleeding at the puncture site. 
 
 
 
Figure 2. Angiographic presentation of aneurysms and CT 
angiographic exploration of bleeding at the puncture site. 
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The vascular surgeon was called for consultation. 
The patient was transferred and operated in the 
Clinic for vascular and endovascular surgery of 
Clincal center of Serbia where hematoma was 
evacuated and suture of left femoral artery was 
performed. Hematological parameters two days 
after femoral artery puncture: RBC 2,56x10 12 /L, Hgb 
80 g/L, Hct 0,25 L/L. In the postoperative course, the 
patient received fraxiparine at a dose of 0,3 ml twice 
daily for the next eight days. After leaving the 
hospital, dual antiplatelet therapy (clopidogrel and 
acetylsalicylic acid) was continued for the next three 
months once a day, followed by acetylsalicylic acid 
onwards. 
 
CASE 2 
A 45-year-old female patient was previously planned 
for the placementof an intracranial stent due to an 
aneurysm on anterior communicating artery. She 
was taking clopidogrel 75 mg twice a day and 
acetylsalicylic acid 100 mg once a day for three days. 
Hematological parameters on admision: RBC 
4,13x10 12 /L, Hgb 128 g/L, Hct 0,409 L/L. Drug-
resistence testing on the „VerifyNow” device showed 
an increased sensitivity of platelets to the action of 
clopidogrel. Administration of clopidogrel was 
stopped for the next five days, it was continued with 
the administration of acetylsalicylic acid 100 mg once 
a day. Also, 0,3 ml of fraxiparin was administered 
twice a day, and then it was proceeded with 
procedure. Through the right femoral artery, the 
guiding catheter was placed in the left internal 
carotid artery, the microcatheter was positioned in 
the aneurysm which was excluded from the 
circulation by placing the coil. As aneurysm was 
resolved by a coil, the dual antiaggregation therapy 
was interrupted in the postoperative course. In the 
early postprocedural period, hematoma formation 
in the groin region occured, and therefore changes 
in the complete blood count: RBC2,87x1012 /L, Hgb 91 
g/L, Hct 0,264 L/L. The patient complained of pain in 
the lower right quadrant of the abdomen in the area 
above the right inguinal ligament. A vascular surgeon 
was consulted, after which a patient was admitted to 
the Clinic for vascular and endovascular surgeryof 
Clinical center of Serbia. CT angiography of the leg 
and abdomen was performed, which showed the 
presence of a lesion in the area of the transition of 
the external iliac to the right common femoral artery 
with extravasation of contrast.[Figure3, Figure4, 
Figure5] Due to active retroperitoneal bleeding, 
conciliar decision was to undergo emergency 
surgical treatment. The patient was postoperative 
hemodynamically stable with palpable pedal pulses. 
 
 
 
Figure 3. CT angiography of the leg and abdomen showing the 
presence of a lesion in the area of the transition of the external 
iliac to the right common femoral artery with extravasation of 
contrast. 
 
 
 
Figure 4. CT angiography of the leg and abdomen showing the 
presence of a lesion in the area of the transition of the external 
iliac to the right common femoral artery with extravasation of 
contrast. 
 
 
 
Figure 5. CT angiography of the leg and abdomen showing the 
presence of a lesion in the area of the transition of the external 
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iliac to the right common femoral artery with extravasation of 
contrast. 
 
CASE 3 
A 47-year-old female patient was admitted to 
perform an endovascular treatment due to the 
presence of aneurysm on the supraclinoid segment 
of the left internal carotid artery, which was 
randomly detected as part of the examination of 
pituitary microadenoma. The width of aneurysm 
neck was 6,5 mm. The patient was planned for 
placing of the flow diverting stent over the aneurysm 
neck. In the preprocedural period, the patient 
received dual antiplatelet therapy (clopidogrel 75 mg 
twice a day and acetylsalicylic acid 100 mg once a 
day) for three days. Drug-resistence testing on the 
„VerifyNow” device showed an increased platelet 
sensitivity to clopidogrel. An aneurysm embolization 
was attempted on two occasions. During the second 
intervention, placement of microcatheter was 
attempted distal from the aneurysm neck in order to 
place a "flow-diverting" stent, which failed even after 
several attempts, and as a result, the procedure was 
interrupted. In the early postprocedural course, the 
condition of the patient worsened in terms of 
confusion, paleness, hypotension, and the presence 
of a larger subcutaneous hematoma in the right 
groin. CT angiography of the leg and abdomen was 
performed, which showed extravasation of contrast 
at the puncture site [Figure 6, Figure 7, Figure 
8,Figure 9, Figure 10]. The patient was transferred to 
the Clinic for vascular and endovascular surgery of 
Clinical center of Serbia where the suture of right 
external iliac artery and evacuation of hematoma 
were performed. During the third hospitalization, the 
patient was again prepared for stent placement with 
dual antiplatelet therapy, and the response to 
clopidogrel was again too strong. This time, it was 
also attempted to place the stent through the 
aneurysm neck, but while the microwirewas passing, 
further distal from the branch of the left middle 
cerebral artery, extravasation of contrast occured. 
Protamine sulfate was administered by venous 
route, which is an antidote for intravenous 
administration of heparin and the contrast 
extravasation was no longer shown. It was 
attempted again to go through with a microcateter 
distally from the neck of aneurysm, but even after 
additional attempts, it failed due to extremely 
unfavorable angioarchitecture.Subsequently, the 
microcatheter was used to access the fundus of 
aneurysm and to place the "pCONUS" stent, and 
then, after placement of several coils, aneurysm was 
excluded from the circulation with less residual filling 
and preserved passage of all blood vessels. 
Postprocedurally, the patient was somnolent, slowed 
down, intubated andwith progressive deterioration 
of consciousness. There was an acute hydrocephalus 
occurrence that was taken cared by the external 
drainage of the cerebrospinal fluid [Figure10]. On 
this occasion, a subdural hematoma was formed, 
which gradually spontaneously absorbed. Ten days 
after embolization, a permanent drainage system, 
ventriculoperitoneal shunt, was placed. It was 
continued with the administration of clopidogrel 
75mg and acetylsalicylic acid 100mg once a day for 
three months, and then only acetylsalicylic acid 
100mg going forward. There has been a recovery in 
the general and neurological condition of the patient 
with a residual right-sided weakness [Figure 11]. 
 
 
 
Figure 6. CT angiography of lower extremities et pelvis showing 
extravasation of contrast at the puncture site.   
 
Figure 7. CT angiography of lower extremities et pelvis showing 
extravasation of contrast at the puncture site. 
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Figure 8. CT angiography of lower extremities et pelvis showing 
extravasation of contrast at the puncture site. 
 
 
 
Figure 9. CT angiography of lower extremities et pelvis showing 
extravasation of contrast at the puncture site. 
 
 
 
Figure 10. Head CT scan showing the occurance of acute 
hydrocephalus. 
 
 
Figure 11. Control head CT scan 1 month after the 
embolisation of aneurysm and VP shunt placement. 
 
DISCUSSION 
Neuroradiological procedures, such as embolization 
of intracranial aneurysms, have been routinely 
applied since their implementation in 1990 to the 
present day. They are performed in general 
anesthesia for better control of pain and immobility 
of patients, control of local blood flow at the site of 
vascular changes via mean arterial pressure, with the 
use of a continuous or bolus dose of heparin by the 
venous line. Dual antiplatelet therapy is used pre- 
and post-procedually in cases of stent 
implatantion.In principle, anticoagulant or 
antiplatelet therapy is widely used in various areas of 
medicine to prevent the development of occlusive 
thrombosis. When it comes to drugs, the prevention 
is achieved by changing the coagulation of the blood. 
Coagulation of the blood, composed of a series of 
proteolytic reactions, is a complex cascade processof 
which the ultimate result is the creation of insoluble 
fibrin. 
The platelet function is regulated by three types 
of compounds. The first group consists of 
compounds that are formed outside of the platelet 
and act on receptors located on the platelet 
membrane: catecholamines, collagen, thrombin, 
prostacyclin. The second group of compounds 
consists of compounds that form in the platelet itself 
but act on membrane receptors: ADP, 
prostaglandins D2 and E2, and serotonin. The third 
group of compounds are produced byplatelet, but 
they act in the platelet itself: thromboxane A2, cyclic 
AMP and GMP. 
In clinical practice, acetylsalicylic acid and 
clopidogrel are generally available. Because of the 
high resistance to clopidogrel antiplatelet activity 
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(16%) measured by the same in vitro platelet 
function tests, a full range of drugs is available. 
Current studies evaluate the efficacy of P2Y12 
receptor inhibitors: prasugrel, ticagrelor, cangrelor, 
elinogrel; then prothrombin antagonists, 
glycoprotein inhibitors, phosphodiesterases, and 
others. 
A response to antiplatelet therapy with 
clopidogrel confirmed by drug-resistence testing on 
the „VerifyNow” device. Verifynow System 
(Accumetrics Inc., San Diego, California, USA) 
monitors the platelet aggregation by agglutination of 
human-fibrinogen-coated granules, which is 
triggered by activated platelets stimulated by 
agonists in citrate full blood. This system measures 
induced platelet aggregation by ADP and 
prostaglandin E1, following an increase in light 
transmission (P2Y12) test. It uses an iso-thrombin 
receptor activating peptide (iso-TRAP) that activates 
platelets regardless of the action of clopidogrel. The 
results are expressed in the PRU (platelet reactivity 
unit) units showing the degree of aggregation 
mediated by P2Y12 receptors. [11,12,13] 
Acetylsalicylic acid irreversibly inhibits the COX-1 
enzyme, then the synthesis of cyclic endoperoxides 
and all prostaglandins that result therefrom. The 
COX-1 inhibition inhibits the synthesis of 
thromboxane, and then prostacyclin and 
prostaglandin E2. Due to irreversible enzyme 
inhibition, once daily dosing of the drug is sufficient. 
There are data indicating that at low doses of 100 mg 
per day, the biosynthesis of thromboxane can be 
selectively inhibited without any influence on 
prostacyclyin synthesis. As a result, small doses of 
acetylsalicylic acid restrict the therapeutic effect of 
prostaglandins that have a significant role in a large 
number of physiological and pathophysiological 
processes in the body (regulation of arterial blood 
pressure, renal function or interaction with 
antihypertensive effect of diuretic, and angiotensin-
converting enzyme, etc.) [14,15,16]  
Simultaneous administration of analgesic drugs 
from a group of non-selective COX1 inhibitors, such 
as ibuprofen and naproxen, can lead to a reduction 
in acetylsalicylic acid by competing for the same 
receptor [17,18] in the preoperative and 
postoperative period. 
Clopidogrel is a drug whose metabolite is a 
platelet aggregation inhibitor. To switch to an active 
metabolite that inhibits platelet aggregation, 
clopidogrel is metabolized by the CYP450 enzyme. 
The active metabolite of clopidogrel selectively 
inhibits adenosine-diphosphate adhesion (ADP) for 
its P2Y12 receptors on platelets and in this way, via 
ADP-mediated activation of the IIb/IIIa glycoprotein 
complex, inhibits platelet aggregation. ADP binds to 
delta granulomas in platelets. ADP achieves its effect 
by binding to its platelet receptors and leads to: 
inhibition of adenylate cyclase by stimulating Gi 
protein and decreasing the concentration of 
intracellular cAMP, the formation of inositol 
triphosphate (IP3) leading to the mobilization of 
calcium from cell depots, the release of arachidonic 
acid leading to the creation of TXA2 and activation 
phospholipase A2. It is believed that ADP exhibits its 
effect by binding to three purinergic receptors: P2Y1, 
P2Y12, and P2X1. It is believed that P2Y12 plays a key 
role in the pathogenesis of arterial thrombus, 
mediating in ADP-induced platelet aggregation, 
potentiating the secretion of granules under the 
action of agonists and potentiating the inhibition of 
the antithrombotic effect of natural regulators of the 
platelet function, prostacyclin. P2Y12 is associated 
with Gi2 protein whose stimulation leads to the 
inhibition of adenylate cyclase and the activation of 
phosphatidylinositol 3 kinase (PI3K). Since this 
receptor is considered to have a central role in the 
formation of a coagulum, it is a target molecule for 
antithrombotic therapy. Due to irreversible binding, 
the effect of inhibition on the affected platelets lasts 
for the entire duration of their plasma life (about 7-
10 days), and re-establishment of platelet function 
occurs after plasma exchange time [19]. This drug 
was approved in 1997 and after showing similar 
antithrombotic efficacy, but also as a significantly 
safer medication for patients, it completely replaced 
ticlopidine. For those patients with a history of 
stroke, it is known that antithrombotic therapy 
reduces incidence of re-ischemic events up to 22%. 
Clopidogrel proved superior to aspirin in reducing 
risk and was recommended for secondary 
prevention of stroke. 
Due to irreversible inhibition of P2Y12 receptor, 
the effect of clopidogrel is present during the life of 
platelets (7-10 days). Cell recovery is expected in the 
period of 3 to 5 days, that is, the platelets are fully 
functional on average for 7 days after taking the last 
dose of the drug. The maximum inhibition of the 
P2Y12 receptor was achieved after 4-5 days of daily 
administration of 75 mg of clopidogrel. This interval 
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can be reduced to 3-5 hours by taking aloading dose 
of 300-600mg. Thus, in addition to the proven 
antithrombotic effect, clopidogrel has its 
disadvantages: its antithrombotic effect is delayed 
due to the necessary metabolism and activation of 
the prolapse, as well as interindividual variability in 
the therapeutic response to the drug. 
The CYP enzyme system is responsible for 40-80% 
metabolism of almost all drugs in the active 
metabolite. Since clopidogrel and lipophilic statins 
are metabolised via the CYP3A4/3A5 enzyme system, 
the inhibition of the formation of the active 
metabolite of clopidogrel and unwanted thrombosis 
can occur [14,15]. Observations and randomized 
clinical studies have shown that the concomitant use 
of clopidogrel and proton pump inhibitors for pre-
operative purposes, and due to gastric irritation, can 
lead to a reduction in the anti-aggregation effect and 
an increase in the number of repeated thromboses 
or ischemic events [20]. Dual anti-aggregation 
therapy is used to prevent the formation of 
thrombus or stent thrombosis. However, 
antiaggregation drugs can cause bleeding as an 
adverse drug reaction [21,22]. In the literature there 
are few studies that investigate increased sensitivity 
of platelets to the action of clopidogrel as opposed to 
postprocedural bleeding aneurysms [23]. For this 
reason, we listed 3 clinical cases with various causes 
of bleeding at the puncture site. 
We believe that preprocedural management 
procedures should be acceptable in order to solve 
the resulting complication and complete the 
procedure. We summarized the mechanism of 
action, the current clinical assessment, and the 
standards for the use of antiagregating drugs in the 
pre-procedural, procedural and postprocedural 
period for the treatment of unruptured aneurysms. 
 
N SEX AGE ANEURYSM 
N1 F 59 ACI BILL. 
N2 F 45 ACOA 
N3 F 47 ACI L.SIN. 
 
Table 1. Anthropological characteristics of the patients. 
 
N Clopidogrel 
bleeding<95-
208<thrombosis 
Acetylsalicylic 
acidbleeding<350-
549<thrombosis 
N1 3 359 
N2 39 525 
N3 14 370 
 
Table 2. Results of the resistance test for clopidogrel and 
acetylsalicylic acid. 
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